Keyphrases
Non-small Cell Lung Cancer (NSCLC)
89%
Lung Cancer
48%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
47%
Tumor
32%
Whole Genome
32%
Pan-cancer Analysis
31%
Phase II Study
22%
Overall Survival
20%
Carboplatin
20%
Chemotherapy
18%
In Cancer
18%
Cancer Genome Atlas
17%
Cancer Types
17%
Pemetrexed
17%
Human Cancer
16%
Phase II Trial
16%
Targeted Therapy
16%
Small Cell Lung Cancer
15%
Lung Adenocarcinoma
13%
Oncology
12%
Docetaxel
12%
Cisplatin
11%
Phase I Study
10%
Non-squamous Non-small Cell Lung Cancer
10%
Bevacizumab
10%
Confidence Interval
10%
Progression-free Survival
10%
Clinical Trials
9%
Early-stage Lung Cancer
9%
Genetic Modification
9%
Previously Treated
8%
Hazard Ratio
8%
Erlotinib
8%
Brain Metastases
8%
Stable Disease
8%
Adjuvant Chemotherapy
8%
Platinum-based Chemotherapy
8%
Tumor Subtype
8%
Patient-derived Xenograft
8%
Epidermal Growth Factor Receptor
8%
Molecular Characterization
7%
Paclitaxel
7%
Radiation Therapy
7%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
7%
Lung Squamous Cell Carcinoma
7%
Stage III Non-small Cell Lung Cancer
7%
Pan-cancer
7%
NCCN Guidelines
6%
Solid Tumors
6%
Clinical Practice Guidelines
6%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Lung Cancer
45%
Chemotherapy
36%
Diseases
25%
Malignant Neoplasm
25%
Overall Survival
23%
Neoplasm
22%
Carboplatin
19%
Small Cell Lung Cancer
18%
Paclitaxel
16%
Pemetrexed
13%
Progression Free Survival
13%
Clinical Trial
12%
Phase II Trials
12%
Docetaxel
11%
Cisplatin
10%
Adverse Event
10%
Epidermal Growth Factor Receptor
10%
Solid Malignant Neoplasm
9%
Bevacizumab
8%
Erlotinib
7%
Chemoradiation Therapy
7%
Brain Metastasis
6%
Biological Marker
6%
Phase III Trials
5%
Gefitinib
5%
Irinotecan
5%
Etoposide
5%
Maximum Tolerated Dose
5%
Lung Adenocarcinoma
5%
Cetuximab
5%
Esophagus Cancer
5%
Adenocarcinoma
5%
Recurrent Disease
5%
Survival Rate
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
78%
Lung Cancer
48%
Malignant Neoplasm
44%
Neoplasm
29%
Diseases
21%
Overall Survival
18%
Small Cell Lung Cancer
17%
Targeted Therapy
13%
Pemetrexed
13%
Oncology
11%
Cancer
11%
Carboplatin
9%
Lung Adenocarcinoma
9%
Radiation Therapy
9%
The Cancer Genome Atlas
8%
Paclitaxel
8%
Recurrent Disease
7%
Arm
7%
Immunotherapy
7%
Squamous Cell Lung Carcinoma
7%
Biological Marker
7%
Bevacizumab
7%
Metastatic Carcinoma
7%
Cancer Types
6%
Progression Free Survival
6%
Positron Emission Tomography
6%
Clinical Trial
6%
Clinical Oncology
6%
Adjuvant Chemotherapy
6%
Lung
6%
Epidermal Growth Factor Receptor
5%
Chemoradiotherapy
5%
Adverse Event
5%
Somatics
5%
Brain Metastasis
5%
Cisplatin
5%